Back to Results
First PageMeta Content



Press Release TxCell announces FDA acceptance of IND for Ovasave IND grants TxCell option of extending current phase 2b study from EU to US Valbonne, France, June 29, 2015 – TxCell SA (FR0010127662 – TXCL), a biotech
Add to Reading List

Document Date: 2015-06-29 12:01:45


Open Document

File Size: 145,79 KB

Share Result on Facebook

Company

TxCell SA / Trizell Holding SA / /

Continent

Europe / /

Country

Germany / Italy / Belgium / France / Austria / United States / United Kingdom / /

/

Event

FDA Phase / /

Facility

EU GMP facility / France’s National Institute / /

/

IndustryTerm

biotechnology / treatment of autoimmune uveitis / a rare disease / technology park / cellular immunotherapy technology / treatment of severe chronic inflammatory diseases / cells products / manufacturing site / cell immunotherapy product / spin-off / /

MedicalCondition

autoimmune uveitis / refractory Crohn’s disease / severe refractory Crohn’s disease / autoimmune diseases / disease / rare disease / severe chronic inflammatory diseases / inflammatory / /

MedicalTreatment

immunotherapies / immunotherapy / cell therapy / /

Organization

Communication Department / United States Food and Drug Administration / Dr Frederik Paulsen Foundation / France’s National Institute for Health and Medical Research / FDA / European Union / Ferring International Center / /

Person

Stéphane Boissel / Pierre Laurent / Neil Hunter / Emma Marshall Julien Perez / Miguel Forte / /

/

Position

Chief Executive Officer / Chief Operating Officer / hunter / marshall / /

Product

ASTrIA / a unique and proprietary product platform / Ovasave / Investigational New Drug / ASTrIA / Ovasave® / CATS29 / /

ProvinceOrState

Indiana / /

Technology

cell therapy / biotechnology / cellular immunotherapy technology / /

SocialTag